Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin + irinotecan + low-dose radiotherapy for advanced/metastatic sarcomas
2023-509215-81-00Phase 2Authorised
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- May 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of trabectedin and irinotecan in soft tissue sarcoma (STS), bone cancer, osteosarcoma (OS) and 5 more, sponsored by Spanish Group for Research on Sarcoma. Primary endpoints: Overall response rate in irradiated nodules and Recommended Phase II dose. Planned start May 2024; status: authorised.
02
Drugs
trabectedinirinotecan
03
Conditions
soft tissue sarcoma (STS)bone cancerosteosarcoma (OS)chondrosarcomaEwing sarcoma
Beyond the preview
Go deeper on 2023-509215-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509215-81-00.